Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support
Precigen Inc. (NASDAQ:PGEN) is one of Goldman Sachs’ top penny stock picks. On January 20, Precigen Inc. (NASDAQ:PGEN) received a significant boost after a consensus paper authored by 16 physicians recommended its flagship drug, PAPZIMEOS, as the standard of care for adults with recurrent respiratory papillomatosis.
The recommendation is a significant boost as it asserts a potential shift from surgical intervention to treating underlying HPV infection that causes recurrent respiratory papillomatosis. The medical condition affects the respiratory tract and is caused by a chronic HPV-6 or HPV-11 infection.
“The speed and agility with which the authors evaluated the evidence and aligned on a recommended first-line treatment and new standard of care for adults with RRP underscores both the unmet need in this disease,” said Helen Sabzevari, President and CEO of Precigen.
Precigen has already transitioned into a commercial-stage company with the US approval of PAPZIMEOS in August 2025. It has become the first and only FDA treatment for adults with RRP. The company has also received a significant boost from the European Medicines Agency, which has validated the Marketing Authorization Application for PAPZIMEOS for the treatment of adults with RRP.
Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing gene and cellular therapies to treat complex, high-need diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Microsoft (MSFT.US) offers voluntary buyout packages to about 60,000 employees: Structural divergence in U.S. employment under AI transformation
In 2026, the U.S. labor market is characterized by both low layoffs and weak hiring. Companies like Microsoft and American Express are leveraging AI to optimize their workforce, while data centers are driving growth in the construction sector. However, entry-level white-collar jobs face increasing pressure, with real wages experiencing negative growth and structural transformation risks becoming more prominent.
Crypto prices
More
